Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection
Permanent URI for this collectionhttps://hdl.handle.net/11147/7148
Browse
2 results
Search Results
Article Citation - WoS: 5Citation - Scopus: 9Using Loofah Reinforced Chitosan-Collagen Hydrogel Based Scaffolds In-Vitro and In-Vivo; Healing in Cartilage Tissue Defects(Elsevier B.V., 2023) Baysan, G.; Kara, Aylin; Gunes, O.C.; Turemis, C.; Akokay, Yilmaz, P.; Husemoglu, R.B.; Kara, Ozenler, A.; Perpelek, M.; 03.01. Department of Bioengineering; 03. Faculty of Engineering; 01. Izmir Institute of TechnologyThe herein article aims to report a new scaffold design as a loofah-reinforced chitosan-collagen hydrogel composite scaffold with three different cross-linker concentrations (0.1, 0.3, and 0.5 wt. /v%). From the analyses, the scaffold crosslinked with 0.5% genipin; collagen-chitosan hydrogel scaffold reinforced with loofah (L-CCol5) was found to be suitable for further in vitro and in vivo studies due to its interconnected porous structure, water content (∼ 97%) and tan delta (0.221 at 1 Hz) values comparable to that of cartilage tissue. In vitro analyses depicted that the L-CCol5 scaffold supported rabbit mesenchymal stem cells (rMSCs) adhesion and proliferation with its non-cytotoxic feature. Moreover, in vivo cartilage healing studies were performed using New Zealand male rabbits in three groups: empty control, cell-free scaffold, and rMSCs-laden scaffold. The elastic moduli of these three groups were 0.69, 0.90, and 1.18 MPa, respectively. Besides, microcomputer tomography (MicroCT) scannings supported the in vivo biomechanical analyses as cell-laden scaffolds showed better osteochondral healing. It can be concluded that the L-CCol5 scaffold could be a promising construct in osteochondral tissue engineering applications. The findings revealed that osteochondral remodeling precedes articular cartilage, providing insight into tailored therapeutic approaches, disease progress, and treatment consequences. © 2023 Acta Materialia Inc.Book Part Citation - WoS: 59Citation - Scopus: 68Stem Cell Therapy for Multiple Sclerosis(Springer, 2019) Genç, Bilgesu; Bozan, Hemdem Rodi; Genç, Şermin; Genç, Kürşad; 01. Izmir Institute of TechnologyMultiple sclerosis (MS) is a chronic inflammatory, autoimmune, and neurodegenerative disease of the central nervous system (CNS). It is characterized by demyelination and neuronal loss that is induced by attack of autoreactive T cells to the myelin sheath and endogenous remyelination failure, eventually leading to functional neurological disability. Although recent evidence suggests that MS relapses are induced by environmental and exogenous triggers such as viral infections in a genetic background, its very complex pathogenesis is not completely understood. Therefore, the efficiency of current immunosuppression-based therapies of MS is too low, and emerging disease-modifying immunomodulatory agents such as fingolimod and dimethyl fumarate cannot stop progressive neurodegenerative process. Thus, the cell replacement therapy approach that aims to overcome neuronal cell loss and remyelination failure and to increase endogenous myelin repair capacity is considered as an alternative treatment option. A wide variety of preclinical studies, using experimental autoimmune encephalomyelitis model of MS, have recently shown that grafted cells with different origins including mesenchymal stem cells (MSCs), neural precursor and stem cells, and induced-pluripotent stem cells have the ability to repair CNS lesions and to recover functional neurological deficits. The results of ongoing autologous hematopoietic stem cell therapy studies, with the advantage of peripheral administration to the patients, have suggested that cell replacement therapy is also a feasible option for immunomodulatory treatment of MS. In this chapter, we overview cell sources and applications of the stem cell therapy for treatment of MS. We also discuss challenges including those associated with administration route, immune responses to grafted cells, integration of these cells to existing neural circuits, and risk of tumor growth. Finally, future prospects of stem cell therapy for MS are addressed.